Kiadis Pharma haalt €12 miljoen financiering op door onderhandse plaatsing van aandelen bij een Amerikaanse biotech investeerder

NEXT STORY
Orion Group Interim Report 1-3/2020
PREV STORY
New 6-year data for Roche’s OCREVUS (ocrelizumab) show earlier treatment initiation nearly halves risk of needing walking aid in relapsing multiple sclerosis
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

X4 Pharmaceuticals to Have Strong Presence at ASH 2021 with Seven Accepted Abstracts Highlighting New Clinical and Scientific Data; Company Reports Third Quarter Financial Results

author_avatar
NASDAQ Market News

Kiniksa Announces Positive Results for Mavrilimumab Phase 2 Trial in Non-Mechanically Ventilated Severe COVID-19 Patients

author_avatar
NASDAQ Market News

ORIC Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update

author_avatar
NASDAQ Market News